[October 20, 2014]

Research and Markets: GSK's Tykerb (lapatinib) HER2-Positive Breast Cancer Treatment Report 2014 - Forecast and Market Analysis to 2023

Research and Markets (http://www.researchandmarkets.com/research/jklzvb/tykerb) has announced the addition of the "Tykerb (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023" report to their offering.

GSK's Tykerb (lapatinib ditosylate monohydrate) is a small-molecule inhibitor of the intracellular tyrosine kinase domain of EGFR and HER2. Tykerb was approved by the FDA in 2007, and by the European Medicines Agency (EMA (News - Alert)) in 2008, for use in loclly-advanced or metastatic breast cancer, in combination with Xeloda (capecitabine). In 2010, the FDA and EMA approved Tykerb for use in HR positive locally advanced or metastatic breast cancer in combination with letrozole.

Scope

• Overview of HER2-Positive Breast Cancer, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
• Detailed information on Tykerb including product description, safety and efficacy profiles as well as a SWOT analysis.
• Sales forecast for Tykerb for the top eight countries from 2013 to 2023.
• Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan and China.

Key Topics Covered:

1 Tables & Figures

2 Introduction

3 Disease Overview

4 Disease Management

5 Competitive Assessment

6 Tykerb (lapatinib)

7 Appendix

For more information visit http://www.researchandmarkets.com/research/jklzvb/tykerb

[ Back To TMCnet.com's Homepage ]